GDC 0425
Alternative Names: GDC-0425; RG-7602Latest Information Update: 05 Nov 2023
At a glance
- Originator Genentech
- Class Antineoplastics; Small molecules
- Mechanism of Action Checkpoint kinase 1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Lymphoma; Solid tumours
Most Recent Events
- 30 Jul 2019 Array Biopharma has been acquired by Pfizer
- 01 May 2014 Genentech completes a phase I trial in Lymphoma and Solid tumours (late-stage disease) in USA and France (NCT01359696)
- 30 Jan 2014 Discontinued - Phase-I for Lymphoma and Solid tumours (late-stage disease) in USA and France (PO)